Archive · 9 Oct 2026
FSSAI Notices Companies Over Celevida GLP+ Health Claims
India’s food regulator has asked several companies to explain advertisements for a nutrition product called Celevida GLP+.
The product was promoted with claims about protein, muscles, immunity and energy.
Some advertising also connected it with GLP-1/GIP therapies.
FSSAI said the product’s name and claims could give shoppers a misleading idea of its benefits.
It also questioned statements about complete nutrition, European purity and BCAA content.
The companies can respond before the regulator decides whether to take further action.
Amazon said the product was no longer available on its marketplace and that sellers must follow Indian laws and its policies.
In separate actions, FSSAI said it suspended a retailer’s licence over expired or rotten food and sanctioned prosecution over unsafe raisins.
FSSAI issued notices to Dr. Reddy’s, Nestle Health Science, Tirupati Wellness, Amazon, Flipkart and Netmeds over claims associated with Celevida GLP+.
The regulator questioned claims about protein support, lean-muscle preservation, muscle strength, immunity and energy metabolism, particularly in relation to GLP-1/GIP therapies.
FSSAI said the product name and advertising could create a misleading association with those therapies and questioned claims of “complete daily nutrition,” European purity and “100% RDA BCAA.”
The companies were asked to explain why action should not be initiated under the Food Safety and Standards Act, 2006; Amazon said the product was no longer available on its marketplace and that third-party sellers must follow applicable rules.
Separately, FSSAI said it suspended Shreyas Retail’s licence over repeated sales of expired or rotten food and sanctioned prosecution against Nex International over unsafe loose raisins.
- Who
- FSSAI; notices named Dr. Reddy’s, Nestle Health Science, Tirupati Wellness, Amazon, Flipkart and Netmeds.
- What
- FSSAI issued show-cause notices over advertising and claims for Celevida GLP+.
- When
- Thursday; one report was published on October 8, 2026.
- Where
- India; the product was advertised on packaging and e-commerce platforms.
- Why
- FSSAI said the claims and product presentation could mislead consumers about health benefits and suggest an association with GLP-1/GIP therapies.
Regulator’s concerns
Company response
Claims and marketplace responsibility
Regulator’s concerns
FSSAI said Celevida GLP+ claims and its presentation could mislead consumers and create an association with GLP-1/GIP therapies.
Company response
Amazon said independent third-party sellers list products on its marketplace, are required to follow applicable laws and its policies, and the product was no longer available there.
- Regulator
- Food Safety and Standards Authority of India (FSSAI)
- Product
- Celevida GLP+
- Notice recipients
- Dr. Reddy’s, Nestle Health Science, Tirupati Wellness, Amazon, Flipkart and Netmeds
- Claims questioned
- Protein support, lean-muscle preservation, muscle strength, immunity support and energy metabolism
- Other representations questioned
- “Complete daily nutrition,” “Imported from Europe for purity” and “100% RDA BCAA”
- Regulatory process
- The companies were asked to show cause why action should not be initiated under the Food Safety and Standards Act, 2006.
- Separate enforcement actions
- FSSAI said it suspended Shreyas Retail’s licence over repeated sales of expired or rotten food and sanctioned prosecution against Nex International over unsafe loose raisins.
- Amazon response
- Amazon said it operates as a marketplace for independent sellers, requires them to follow Indian laws and its policies, and had removed the product from its marketplace.
Sources
FSSAI issues notices to Dr Reddy’s, Amazon, Flipkart and Netmeds over misleading health claims
FSSAI flags misleading protein claims, issues notices to Dr Reddy’s, Nestle, Flipkart, Amazon and others
‘Lean muscle’ claims under scanner: FSSAI issues notices to Dr Reddy’s, Nestle, Amazon, Flipkart
Dr Reddy's, Nestle, Amazon, Flipkart Get Notice Over Misleading Health Claims
